Compare IVVD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVVD | NYXH |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.9M | 161.9M |
| IPO Year | 2021 | 2021 |
| Metric | IVVD | NYXH |
|---|---|---|
| Price | $0.61 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $8.75 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 5.2M | 217.1K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | $213.98 |
| Revenue Next Year | $41.42 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $1.26 |
| 52 Week High | $3.07 | $8.59 |
| Indicator | IVVD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 32.98 |
| Support Level | N/A | $1.26 |
| Resistance Level | $1.01 | $1.70 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 1.97 | 2.78 |
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.